Heart attack

Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 23/December/2017, 2.13 am
Natural product-derived therapy for improving cardiac contractility and attenuating pathogenesis associated with Myocardial infarction: A pharmaceutical mixture encompassing Withaferin A, Hesperidin and Isoorientin (WAHI) decreases GRK2 (G Protein-Coupled Receptor Kinase 2) and GM-CSF (Granulocyte-macrophage colony-stimulating factor) expression, increases cardiac contractility, inhibits undue leucocyte activation and invasion, suppresses recruitment of inflammatory cells, inhibits left ventricular rupture, promotes heart healing and inhibits glucose intolerance, via up regulation of its target gene, 23/December/2017, 2.13 am 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study, from Department of Medicine, Division of Cardiology, Dept of Cell Biology, and Department of Molecular Genetics, Duke University Medical Center, Durham, North Carolina,…

read more

Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 19/December/2017, 10.54 pm
Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression, and inhibits dilated cardiomyopathy via up regulation of its target gene, 19/December/2017, 10.54 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What we say: Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Cardiac rejuvenation therapy: Cardiac rejuvenation therapy: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN) suppresses tumor suppressor INK4a/p16 expression,…

read more

Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMSFN] encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 19/December/2017, 10.31 pm,
Regenerative therapy for regaining the lost cardiomyocytes in Myocardial patients:  A pharmaceutical mixture [PMSFN] encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases the expression of ERBB2/Her2 and promotes dedifferentiation  of cardiomyocytes via down regulation of its target gene, 19/December/2017, 10.31 pm, 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say A recent study from the Department of Biological Regulation, Weizmann Institute of Science, Rehovot 76100, Israel shows that “ERBB2 triggers mammalian heart regeneration by promoting cardiomyocyte dedifferentiation and proliferation.” This study was published, in the 6 April…

read more

Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 19/December/2017, 10.17  pm
Molecular therapy for heart regeneration and repair: A therapeutic mix encompassing Pyridoxamine (PM) and Sulforaphane (SFN)  increases Agrin expression, activates Yap and ERK-mediated signaling,  replaces scar tissue with functional cardiomyocytes, and promotes cardiomyocyte regeneration and repair after myocardial infarction, via up regulation of its target gene, 19/December/2017, 10.17  pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say: A recent study from Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot 76100, Israel; Department of Biomedical Engineering, Duke University, Durham, North Carolina 27708,…

read more

Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 17/December/2017,  11.03 pm
Molecular therapy for Cardiomyopathy: A pharmaceutical mixture (PMSFN) encompassing  Pyridoxamin (PM) and Sulphoraphane (SFN) decreases the expression of Sox6, restores the balance between slow- and fast-twitch myofiber proteins and alleviates Cardiomyopathy via up regulation of its target gene, 17/December/2017,  11.03 pm 960 720 Dr Boomi's Genom-2-Discovery Center

Introduction: What they say   A study from the Department of Cardiology, Boston Children’s Hospital, Harvard Medical School, Boston, Massachusetts, USA; and Harvard Stem Cell Institute, Harvard University, Cambridge, Massachusetts, USA shows that “Trbp regulates heart function through microRNA-mediated Sox6 repression.” This…

read more

Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS,  16/December/2017, 11.49 pm
Natural product-derived combinatorial therapy for Myocardial Infarction: A pharmaceutical mixture encompassing Pyridoxamine (PM) and Sulforaphane (SFN) inhibits DNA damage responses, induces telomerase expression, inhibits telomere shortening, and promotes cardiomyocyte survival after myocardial infarction via up regulation of PNUTS,  16/December/2017, 11.49 pm 960 720 Dr Boomi's Genom-2-Discovery Center

What they say:  A recent study from the Institute for Cardiovascular Regeneration, Centre of Molecular Medicine, Frankfurt, Germany shows that “MicroRNA-34a regulates cardiac ageing and function.” This study was published, in the 7 March  2013 issue of Nature,  by Prof Dimmler, Boon, and others. What we…

read more
Start Typing